Humira (adalimumab)
Sponsors
Abbott, Samsung Bioepis Co., Ltd., Applied Molecular Transport
Conditions
AsthmaPlaque PsoriasisPsoriasisRheumatoid ArthritisUlcerative Colitis
Phase 2
A Dose-Finding Study to Evaluate the Safety, Efficacy and Pharmacokinetics of Adalimumab in Subjects With Refractory Asthma
WithdrawnNCT00512863
Start: 2007-08-31Target: 272Updated: 2007-11-06
Study of the Efficacy and Safety of AMT-101 in Combination With Adalimumab in Subjects With Ulcerative Colitis (MARKET)
CompletedNCT05372939
Start: 2021-02-05End: 2022-07-13Updated: 2022-09-14
Phase 3
A Canadian Open-Label Access Program to Evaluate Adalimumab When Added to Inadequate Therapy for the Treatment of Psoriasis
CompletedNCT00513370
Start: 2007-09-30Updated: 2011-04-11
A Study Comparing SB5 to Humira® in Subjects With Moderate to Severe Rheumatoid Arthritis Despite Methotrexate Therapy
CompletedNCT02167139
Start: 2014-05-31End: 2015-10-31Updated: 2017-08-17
Phase 4
Evaluation of Quality of Life Changes in Puerto Rican Subjects With Active Rheumatoid Arthritis Treated With Humira
TerminatedNCT00761514
Start: 2006-11-30End: 2008-08-31Updated: 2009-11-19
Pharmacokinetics, Efficacy, Safety, and Immunogenicity of SB5 Versus Humira in Subjects With Moderate to Severe Chronic Plaque Psoriasis
CompletedNCT05510063
Start: 2022-08-04End: 2023-05-04Updated: 2023-05-25